NCT06287749Recruiting
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
French Assessment of Minimal Residual Disease by Liquid Biopsies in Pancreatic Ductal Adenocarcinoma Patients
Source: ClinicalTrials.gov · Last updated 10 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice. Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence. Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after 1. curative-intended surgery and 2. adjuvant chemotherapy. FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 37 (estimated)
- First submitted
- 8 Feb 2024
- Start date
- 1 Mar 2024
- Primary completion date
- 31 Oct 2028
- Lead sponsor
- University Hospital, Montpellier
- Diseases
- Pancreatic cancer
- NCT number
- NCT06287749
What you commit to
- Study type: Observational
- Planned participants: 37
- From 1 Mar 2024 to the primary completion date, 31 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.
Other illness
- Hereditary pancreatic cancer.
Age
- Pregnant or nursing woman, or in childbearing age and not willing to use contraception
Other
- Verified distant metastases.
- Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study.
- Adult subject to a legal protection
- Not covered by Health insurance
- Patient unable to understand and sign written informed consent.
Who the study is looking for
- Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.
- Age 18 years or older.
- Scheduled for curative intent surgical resection.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Montpellier Coordinator of this site? Confirm its status | Montpellier | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.